Allogeneic NK Cell therapy (Tianjin Medical University Cancer Institute And Hospital)

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameAllogeneic NK Cell therapy (Tianjin Medical University Cancer Institute And Hospital)
Drug Alias NameSK-NK
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursAscitesNeoplasm Metastasis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTianjin Medical University Cancer Institute And Hospital
China Registration ClassN/A

Develop Information

Active CompaniesCells First Biotechnology (Beijing) Co LtdTianjin Medical University Cancer Institute And Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursAscitesNeoplasm Metastasis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A